Zhi Xu

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 13

Top Topics

Top Venues

Archiv der Pharmazie

Chemistry & biodiversity

Molecules (Basel, Switzerland)

Drug development research

This page only lists publications with an associated author ORCID identifier.

Publications

Zhi Xu, Li Wang, Hongyan Hu
Current scenario of fused pyrimidines with in vivo anticancer therapeutic potential. Archiv der Pharmazie (2024)
Zhi Xu, Li Wang, Hongyan Hu
Current scenario of fused pyrimidines with in vivo anticancer therapeutic potential. Archiv der Pharmazie 357 (8) (2024)
Zhi Xu, Li Wang, Hongyan Hu
Current scenario of fused pyrimidines with in vivo anticancer therapeutic potential. Archiv der Pharmazie 357 (8) (2024)
Zhaoyang Li, Meiling Zeng, Keyong Geng, Donna Lai, Zhi Xu, Wei Zhou
Chemical Constituents and Hypoglycemic Mechanisms of Dendrobium nobile in Treatment of Type 2 Diabetic Rats by UPLC-ESI-Q-Orbitrap, Network Pharmacology and In Vivo Experimental Verification. Molecules (Basel, Switzerland) 28 (6) (2023)
Zhaoyang Li, Meiling Zeng, Keyong Geng, Donna Lai, Zhi Xu, Wei Zhou
Chemical Constituents and Hypoglycemic Mechanisms of Dendrobium nobile in Treatment of Type 2 Diabetic Rats by UPLC-ESI-Q-Orbitrap, Network Pharmacology and In Vivo Experimental Verification. Molecules (Basel, Switzerland) 28 (6) (2023)
Zhi Xu, Xiaoyan Zhang, Jie Liu, Shijia Zhao, Junna Liu, Wei Zhou
Design, Synthesis, and Biological Evaluation of Novel Amyl Ester Tethered Dihydroartemisinin-Isatin Hybrids as Potent Anti-Breast Cancer Agents. Chemistry & biodiversity (2023)
Shaohuan Liu, Shu Wang, Dan Xu, Bowen Pan, Linzhi Chen, Shijia Zhao, Zhi Xu, Wei Zhou
Novel ester tethered dihydroartemisinin-3-(oxime/thiosemicarbazide)isatin hybrids as potential anti-breast cancer agents: Synthesis, in vitro cytotoxicity and structure-activity relationship. Drug development research (2023)
Zhi Xu, Xiaoyan Zhang, Jie Liu, Shijia Zhao, Junna Liu, Wei Zhou
Design, Synthesis, and Biological Evaluation of Novel Amyl Ester Tethered Dihydroartemisinin-Isatin Hybrids as Potent Anti-Breast Cancer Agents. Chemistry & biodiversity 20 (3) (2023)
Zhi Xu, Xiaoyan Zhang, Jie Liu, Shijia Zhao, Junna Liu, Wei Zhou
Design, Synthesis, and Biological Evaluation of Novel Amyl Ester Tethered Dihydroartemisinin-Isatin Hybrids as Potent Anti-Breast Cancer Agents. Chemistry & biodiversity 20 (3) (2023)
Zhaoyang Li, Meiling Zeng, Keyong Geng, Donna Lai, Zhi Xu, Wei Zhou
Chemical Constituents and Hypoglycemic Mechanisms of Dendrobium nobile in Treatment of Type 2 Diabetic Rats by UPLC-ESI-Q-Orbitrap, Network Pharmacology and In Vivo Experimental Verification. Molecules (Basel, Switzerland) 28 (6) (2023)
Gaoli Dong, Yingchun Jiang, Feng Zhang, Fengyun Zhu, Junna Liu, Zhi Xu
Recent updates on 1,2,3-, 1,2,4-, and 1,3,5-triazine hybrids (2017-present): The anticancer activity, structure-activity relationships, and mechanisms of action. Archiv der Pharmazie (2022)
Ya-Zhou Zhang, Hong-Zhi Du, Hai-Lin Liu, Qian-Song He, Zhi Xu
Isatin dimers and their biological activities. Archiv der Pharmazie 353 (3) (2020)
Xuemei Ge, Zhi Xu
1,2,4-Triazole hybrids with potential antibacterial activity against methicillin-resistant Staphylococcus aureus. Archiv der Pharmazie 354 (1) (2020)